Search the Newsreel

iMDx to Release Second Quarter Results on August 10, 2026

Insight Molecular Diagnostics Inc. (iMDx) announced it will release its second-quarter 2026 financial results after market close on August 10, 2026, followed by a live Zoom webinar for discussion. Additionally, iMDx's CEO and CFO will participate in the 11th Annual Needham Virtual MedTech & …

Earnings call transcript: Niagen Bioscience posts q2 2026 growth, lifts spending

Niagen Bioscience (CDXC) reported Q2 2026 revenue of $29.8 million, driven by growth in its Tru Niagen supplement and e-commerce, but net income dropped to $1 million ($0.01 per diluted share) due to increased marketing and product development spending. The company is transitioning into …

QIAGEN NV Revenue Breakdown – BIVA:QIA/N

QIAGEN NV (BIVA:QIA/N) generated 37.68 billion MXN in revenue last year. Its top-performing segment was Diagnostic Solutions, contributing 14.48 billion MXN. The United States was the largest regional contributor, accounting for 18.00 billion MXN of the total revenue.

Is Niagen Bioscience Inc (NAGE) Undervalued After Q2 Earnings Mi

Niagen Bioscience (NASDAQ:NAGE) Announces Quarterly Earnings Results, Meets Expectations

Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.01 EPS, which met analyst expectations. The company demonstrated a net margin of 14.29% and a return on equity of 22.68%. Despite the stock trading near its 52-week low, analysts maintain a generally positive "Buy" rating with …

Niagen Bioscience outlines 10% to 15% 2026 e-commerce growth while positioning Niagen Plus and NB4168 for 2027 traction

Earnings Call Insights: Niagen Bioscience (NAGE) Q2 2026 MANAGEMENT VIEW * "This quarter marks another important milestone in the evolution of Niagen Bioscience" (CEO & Director Robert Fried) and "today, we are becoming something much broader, a science-driven platform company built around the biology …

IAMGOLD Corp expected to post earnings of 52 cents a share - Earnings Preview

IAMGOLD Corp (TSX:IMG) is projected to report earnings of 52 cents per share, according to a Reuters earnings preview. The full article can be accessed by TradingView subscribers.

Niagen Bioscience, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NAGE) 2026-08-04

iA Financial Corporation Inc. Announces the Payment of a Dividend on Its Common Shares

QUEBEC CITY, August 04, 2026--(BUSINESS WIRE)--The Board of Directors of iA Financial Corporation Inc. (TSX: IAG) announced today the payment of a quarterly dividend of $1.1000 per outstanding common share for the quarter ended June 30, 2026. This dividend will be payable on September …

Release according to Article 40, Section 1 of the WpHG

QIAGEN N.V. has released a notification regarding voting rights, as informed by the AFM. T. Rowe Price Group, Inc. reported a transaction on July 29, 2026, showing a capital interest and voting rights distribution of 4.97% in QIAGEN N.V. The company emphasizes it is …

Lucid Diagnostics to Participate in Upcoming Investor Conferences

Lucid Diagnostics Inc. announced its participation in two upcoming investor conferences: the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10, 2026, and the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. Management will hold 1x1 meetings and a …

Diageo boss Lewis must convince sceptics as he unveils big reset on Thursday

Diageo's CEO, Dave Lewis, is set to unveil a new strategy aimed at boosting sales and competitiveness without sacrificing profitability. Analysts from JPMorgan, Deutsche Bank, and UBS express skepticism regarding the company's ability to recover sales volume and maintain profit margins, especially amidst anticipated …

Lucid Diagnostics Sets Boston Fireside Chat and Virtual Meetings

Lucid Diagnostics (Nasdaq: LUCD), a cancer prevention diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), announced its participation in two upcoming investor events. Management will attend the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10, 2026, and host a fireside …

Insight Molecular Diagnostics updates financial calendar ahead of quarterly results webinar

Insight Molecular Diagnostics announced updates to its financial calendar, scheduling its Q2 2026 results webinar for August 10, 2026, at 5 p.m. ET. Additionally, management will participate in the Needham Virtual MedTech & Diagnostics 1x1 Conference on August 11, 2026. This news brief was …

Segall Bryant & Hamill LLC Lowers Holdings in Qiagen N.V. $QGEN

Segall Bryant & Hamill LLC reduced its stake in Qiagen N.V. by 24.5% in the first quarter, selling 36,110 shares but still retaining 111,177 shares worth approximately $4.45 million. Despite this reduction, other institutional investors like Groupe la Francaise, Janus Henderson Group PLC, Amundi, …

Weekly Recap: Co-Diagnostics, Inc. Q2 results date and Bundibugyo test

Co-Diagnostics, Inc. (NASDAQ:CODX) is scheduled to report its Q2 2026 financial results on August 13 after market close, followed by an earnings call. The company also announced a proof-of-concept extraction-free test for the Bundibugyo virus, designed for rapid detection during outbreaks.

Arrowstreet Capital Limited Partnership Has $4.75 Million Holdings in Diageo plc $DEO

Arrowstreet Capital Limited Partnership significantly increased its stake in Diageo plc, purchasing an additional 48,487 shares to bring its total holdings to 63,767 shares, valued at approximately $4.75 million. Other institutional investors also expanded their positions in Diageo, with institutional investors and hedge funds …

BCAL Diagnostics (ASX:BDX) Reaches Its High as US Validation Broadens the Cancer Pipeline

Niagen Bioscience (NAGE) Earnings Date and Reports 2026

EKF Diagnostics Cancels 110,000 Shares in Targeted Buyback

Why Integral Diagnostics Ltd (ASX:IDX) Is Attracting Investor Interest in Healthcare

Quest Diagnostics Raises 2026 Outlook as Testing Demand Accelerates

Quest Diagnostics (DGX) has increased its 2026 revenue and adjusted earnings guidance, attributing the improved outlook to accelerated testing demand across various channels. While the company's Q2 results exceeded expectations, driven by volume growth, concerns remain regarding the impact of lower-margin partnerships and increased …

Qiagen NV expected to post earnings of 60 cents a share - Earnings Preview

Qiagen NV is projected to report earnings of 60 cents per share. This information comes from a Refinitiv earnings preview. The full article content is available on TradingView, which aggregates news from various sources including Reuters.

Daily Special: FlexiRoam, Acusensus, WA Gold, Matsa Resources, Lumos Diagnostics

Carriage Services (CSV) Q2 Earnings Report Preview: What To Look For

Carriage Services (CSV) is set to release its Q2 earnings report, with analysts expecting a 6.6% year-on-year revenue growth after a flat revenue performance in the previous year's same quarter. The company has a history of rarely missing Wall Street's revenue estimates, and its …

IAMGOLD Corporation (TSX:IMG) Brings Gold Stocks Into Sharp Focus

This article focuses on Canadian gold producers, particularly IAMGOLD Corporation (TSX:IMG), as the reporting season highlights the importance of operational quality, disciplined execution, project delivery, and sustainable cash generation in the mining sector. It mentions that companies like IAMGOLD, Lundin Gold, New Gold, and …

Jobs at risk across Diageo’s distilleries in Scotland

Hundreds of jobs are at risk across Diageo’s distilleries in the Scottish Highlands and Islands, with 38 positions potentially being cut as part of a global redundancy program. The local union, GMB Scotland, has accused Diageo of rejecting alternatives to compulsory redundancies and ignoring …

Niagen Bioscience (NAGE) FDA Approvals, PDUFA Dates & Drug Alerts 2026

Niagen Bioscience (NAGE) is advancing its drug candidate NB4168 for the treatment of Ataxia Telangiectasia. The company recently announced that it has selected Evotec as a contract research organization to support NB4168's development and previously received Rare Pediatric Disease designation from the FDA for …

Niagen Bioscience selects Evotec for rare disease drug studies

Niagen Bioscience has partnered with Evotec to support the development of NB4168, an oral small-molecule candidate for Ataxia Telangiectasia (A-T), a rare pediatric genetic disease. Evotec will conduct pharmacokinetic and pharmacodynamic studies and validate bioanalytical methods for NB4168. Niagen Bioscience plans to submit an …

Evotec to Study NB4168 for Rare Pediatric Disease With No Approved Treatment

Niagen Bioscience has partnered with Evotec, a global life science company, to advance the preclinical development of NB4168, a proprietary oral small-molecule candidate for Ataxia Telangiectasia (A-T), a rare pediatric genetic disease with no approved treatments. Evotec will conduct pharmacokinetic, pharmacodynamic, and bioanalytical studies …

Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast

Co-Diagnostics, Inc. (Nasdaq: CODX) announced that it will release its second quarter 2026 financial results on Thursday, August 13, 2026, after market close. The company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss the …

EKF Diagnostics Cancels 80,000 Shares in Targeted Buyback

Diageo plc (NYSE: DEO) details voting rights and share awards

Diageo plc has reported its share capital and senior management share dealings for July 2026. The company's issued capital includes 2,432,397,125 Ordinary Shares, with 205,812,357 held in Treasury without voting rights, resulting in 2,226,584,768 total voting rights. Additionally, Diageo is rectifying its share register …

Carriage Services, Inc. $CSV Shares Sold by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership reduced its stake in Carriage Services (NYSE:CSV) by 18.1% in the first quarter, selling 25,021 shares and retaining 113,524 shares valued at $5.2 million. Despite this, institutional investors and hedge funds still own 66.46% of the company, and analysts maintain …

Diageo to Report FY26 Earnings: What Should Investors Know?

Co-Diagnostics Raises Capital Through Warrant Inducement Ahead of FDA Review

Co-Diagnostics, which has no FDA-cleared products, raised capital on July 30, 2026, by inducing existing warrant holders to exercise early in exchange for new warrants. This move aims to secure immediate cash without dilutive equity pricing while the company awaits a crucial FDA 510(k) …